Olesen J (2018) International classification of headache disorders. Lancet Neurol 17(5):396–397

Article  PubMed  Google Scholar 

Lantéri-Minet M, Duru G, Mudge M et al (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31(7):837–850

Article  PubMed  Google Scholar 

Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15:70–78

Article  PubMed  Google Scholar 

Buse DC, Manack AN, Fanning KM et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52(10):1456–70

Article  PubMed  Google Scholar 

Natoli J, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30(5):599–609

Article  CAS  PubMed  Google Scholar 

Bonafede M, Sapra S, Shah N et al (2018) Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache 58(5):700–14

Article  PubMed  Google Scholar 

Stovner LJ, Nichols E, Steiner TJ et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 17(11):954–976

Article  Google Scholar 

The Evidence Centre (2020) The state of the migraine nation: what is the impact of migraine in the UK? Rapid research review London: The Migraine Trust. Available from: https://migrainetrust.org/wp-content/uploads/2021/08/State-of-the-Migraine-Nation-impact-rapid-review.pdf. Accessed 2 May 2023

Negro A, Sciattella P, Rossi D et al (2019) Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain 20(1):1–12

Article  Google Scholar 

Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37(4):631–649

Article  PubMed  Google Scholar 

National Institute for Health and Care Excellence (NICE) (2021) Headaches in over 12s: diagnosis and management. NICE. https://www.nice.org.uk/guidance/cg150. Accessed 19 Sept 2023.

Scottish Intercollegiate Guidelines Network (SIGN) (2023) Pharmacological management of migraine. Edinburgh: SIGN. https://www.sign.ac.uk/our-guidelines/pharmacological-management-of-migraine/. Accessed 19 Sept 2023.

Steiner TJ (2013) Headache in the world: public health and research priorities. Expert Rev Pharmacoecon Outcomes Res 13(1):51–57

Article  PubMed  Google Scholar 

Ailani J, Burch RC, Robbins MS et al (2021) The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021–39

Article  PubMed  Google Scholar 

National Institute for Health and Care Excellence (NICE) (2012) Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE. Accessed 19 Sept 2023.

Varnado OJ, Hoyt M, Ye W et al (2022) Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication. Curr Med Res Opin 38(8):1451–1457

Article  CAS  PubMed  Google Scholar 

Zheng H, Huang SL, Chen YY et al (2021) Topiramate, acupuncture, and BoNT-A for chronic migraine: a network meta-analysis. Acta Neurol Scand 143(5):558–568

Article  CAS  PubMed  Google Scholar 

Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 372:n160

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn. Chichester, Wiley

Book  Google Scholar 

Rendas-Baum R, Bloudek LM, Maglinte GA et al (2013) The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22:1123–33

Article  PubMed  Google Scholar 

Feng Y-S, Kohlmann T, Janssen MF et al (2021) Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res 30:647–673

Article  PubMed  Google Scholar 

Yang M, Rendas-Baum R, Varon SF et al (2011) Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 31(3):357–367

Article  PubMed  PubMed Central  Google Scholar 

Snapinn SM, Jiang Q (2007) Responder analyses and the assessment of a clinically relevant treatment effect. Trials 8:1–6

Article  Google Scholar 

Abugov R, Clark J, Higginbotham L et al (2023) Should responder analyses be conducted on continuous outcomes? Pharm Stat 22(2):312–327

Article  PubMed  Google Scholar 

Collister D, Bangdiwala S, Walsh M et al (2021) Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses. J Clin Epidemiol 134:95–102

Article  PubMed  Google Scholar 

StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.

Phillippo DM. Multinma: An R package for Bayesian network meta-analysis of individual and aggregate data: version 4.1.3. 2021.

R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.

Fernandes GC, Knijnik L, Lopez J et al (2020) Network meta-analysis of His bundle, biventricular, or right ventricular pacing as a primary strategy for advanced atrioventricular conduction disease with normal or mildly reduced ejection fraction. J Cardiovasc Electrophysiol 31(6):1482–1492

Article  PubMed  Google Scholar 

Page MJ, Higgins JP, Sterne JA (2019) Assessing risk of bias due to missing results in a synthesis. Cochrane handbook Syst Rev Interv 349–74

Phillips M (2021) Healthcare Recommendations: Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) Approach. Evid Based Orthop 19–23

Detke HC, Goadsby PJ, Wang S et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dodick DW, Silberstein S, Saper J et al (2007) The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 47(10):1398–408

Article  PubMed  Google Scholar 

Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122

Article  CAS  PubMed  Google Scholar 

Sakai F, Suzuki N, Kim BK et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092–101

Article  PubMed  PubMed Central  Google Scholar 

Aurora S, Dodick D, Turkel C et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793–803

Article  CAS  PubMed  Google Scholar 

Diener H, Dodick D, Aurora S et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804–814

Article  CAS  PubMed  Google Scholar 

Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365–e1377

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dodick DW, Lipton RB, Silberstein S et al (2019) Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 39(9):1075–1085

Article  PubMed  Google Scholar 

Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434

Article  CAS  PubMed  Google Scholar 

Rothrock JF, Adams AM, Lipton RB et al (2019) FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache 59(10):1700–13

Article  PubMed  PubMed Central  Google Scholar 

Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030–1040

Article  CAS  PubMed  Google Scholar 

Yu S, Kim B-K, Wang H et al (2022) A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 23(1):146

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silberstein SD, Lipton RB, Dodick DW et al (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47(2):170–80

Article  PubMed  Google Scholar 

Silberstein S, Lipton R, Dodick D et al (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49(8):1153–62

Article  PubMed  Google Scholar 

Lipton RB, Rosen NL, Ailani J et al (2016) OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia 36(9):899–908

Article  PubMed